Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Impact of Various Acceleration Techniques on En-masse Retraction of Maxillary Anterior Teeth

NCT07873853 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-11-01
Last updated
2026-10-14

Condition(s) studied

Accelerate Tooth Movement

Investigational drug(s) / intervention(s)

low level LAZER therapy.Retraction of Maxillary Anterior Teeth (en-mass) with conventional methods.Piezocision-assisted orthodontic retraction

low level LAZER therapy.: Application of low-level laser therapy (LLLT) as an adjunct to conventional en-masse retraction to accelerate tooth movement.

Retraction of Maxillary Anterior Teeth (en-mass) with conventional methods.: Standard en-masse retraction using conventional orthodontic mechanics without adjunctive acceleration techniques.

Piezocision-assisted orthodontic retraction: Minimally invasive surgical procedure (piezocision) used alongside conventional mechanics to facilitate accelerated tooth movement during en-masse retraction.

Study summary

Impact of Various Acceleration Techniques on En-masse Retraction of Maxillary Anterior Teeth: A Digital Software Evaluation (Comparative Clinical Study)

Eligibility

Sex
ALL
Min age
14 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age between 14 to 25. 2. Patients who need upper or all four first premolar extraction for canine retraction. 3. No systemic disease. 4. No previous extraction of permanent teeth. 5. Not receiving medical treatment that could interfere with bone metabolism. 6. A good level of oral hygiene. 7. No periodontal disease or radiographic evidence of bone loss Exclusion Criteria: 1\. Periodontally compromised patients. 2. Missing teeth. 3. Systemic diseases. 4. Drug dependencies. 5. Uncooperative patient. \-

Primary outcome measure(s)

  • En-masse retraction of maxillary anterior teeth — Base line (T0), 1 month (T1), 2months (T2), and 3months(T3) after the start of retraction

Trial sites (1)

FacilityCityRegionStatus
Department of Orthodontic,Faculty Of Dental Medicine ,AL-Azhar University ,Assuit Branch Asyut Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07873853 on ClinicalTrials.gov ↗ ← All trials in Egypt